Comparison of Inhibitory Effects between Cetuximab and Cisplatin on Colon Cancer SW480 Cell Line
Article Sidebar
Main Article Content
บทคัดย่อ
Cancer is still one of the more severe diseases that endangers the life of a human being, especially in the present day. Globally, colorectal cancer is a very predominant cancer and the second principal contributor to cancer-related fatalities across all ages, both adults and children. Currently available treatments include surgery, radiotherapy, chemotherapy, and immunotherapy. Chemotherapy is an established modality in the therapy of cancer, and platinum-based drugs demonstrated activity against several tumours. Here, cancer cell lines were grown in ELISA plates in media until ~80% monolayer confluence. Cetuximab (Cetx) was tested for cytotoxicity on the SW480 colon cancer cell line at six serial concentrations ranging from 2.5 to 0.0781 µg/mL. Similarly, the same cell line was exposed to six serial levels of cisplatin (Cisp.), varying from 100 to 3.125 µg/mL, for 24 hours. Cells without any treatment served as controls. Cell viability was monitored by measuring OD with an ELISA reader after staining with crystal violet. The findings revealed a significant result at the statistical level (P < 0.05). in the cell-killing impacts of cetuximab and cisplatin in colon cancer cells. These findings emphasize the potential value of cetuximab's anti-tumour activity when used alongside traditional platinum-based chemotherapy and support its use in targeted cancer therapy.
Article Details
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เอกสารอ้างอิง
Pai, R.; Soreghan, B.; Szabo, I. L.; Pavelka, M.; Baatar, D.; Tarnawski, A. S. Prostaglandin E2 Transactivates EGF Receptor: A Novel Mechanism for Promoting Colon Cancer Growth and Gastrointestinal Hypertrophy. Nat. Med. 2002, 8(3), 289–293. https://doi.org/10.1038/nm0302-289
Fahrer, J.; Kaina, B. O6-methylguanine-DNA Methyltransferase in the Defense Against N-nitroso Compounds and Colorectal Cancer. Carcinogenesis 2013, 34(11), 2435–2442. https://doi.org/10.1093/carcin/bgt275
Sadanandam, A.; Lyssiotis, C. A.; Homicsko, K.; Collisson, E. A.; Gibb, W. J.; Wullschleger, S.; Ostos, L. C. G.; Lannon, W. A.; Grotat, C.; Beer, M.; Mahajan, N.; Gratchev, A.; Venkatasubramanian, M.; Dow, J.; Mitsuiki, M.; Bandyopadhyay, S.; Vermeulen, J. P.; Arumugam, P. U.; Silberert, A.; Vakoc, C. R.; Song, J. S.; Hanahan, D. A Colorectal Cancer Classification System that Associates Cellular Phenotype and Responses to Therapy. Nat. Med. 2013, 19(5), 619–625. https://doi.org/10.1038/nm.3175
Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy Plus Cetuximab for Locoregionally Advanced Head and Neck Cancer: 5-year Survival Data from a Phase 3 Randomized Trial, and Relation Between Cetuximab-induced Rash and Survival. Lancet Oncol. 2010, 11(1), 21–28. https://doi.org/10.1016/S1470-2045(09)70311-0
Douillard, J. Y.; Pirker, R.; O'Byrne, K. J.; Kerber, A.; Störkel, S.; von Pawel, J.; Gatzemeier, U.; Shepherd, F. A.; Trigo, J. M.; Spigel, D. R.; Boyer, M.; Schirpke, B.; Klingelschmitt, G.; Ochs, J. S. Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non-small-cell Lung Cancer. J. Thorac. Oncol. 2014, 9(5), 717–724. https://doi.org/10.1097/JTO.0000000000000141
Sridhar, S. S.; Seymour, L.; Shepherd, F. A. Inhibitors of Epidermal-growth-factor Receptors: A Review of Clinical Research with a Focus on Non-small-cell Lung Cancer. Lancet Oncol. 2003, 4(7), 397–406. https://doi.org/10.1016/S1470-2045(03)01137-9
Siddik, Z. H. Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance. Oncogene 2003, 22(47), 7265–7279. https://doi.org/10.1038/sj.onc.1206933
Boulikas, T.; Vougiouka, M. Cisplatin and Platinum Drugs at the Molecular Level: A Review. Oncol. Rep. 2003, 10(6), 1663–1682. https://doi.org/10.3892/or.10.6.1663
Maduro, J. H.; Pras, E.; Willemse, P. H. B.; de Vries, E. G. E. Acute and Long-term Toxicity Following Radiotherapy Alone or in Combination with Chemotherapy for Locally Advanced Cervical Cancer. Cancer Treat. Rev. 2003, 29 (6), 471–488. https://doi.org/10.1016/S0305-7372(03)00117-8
Pinzani, V.; Bressolle, F.; Haug, I. J.; Galtier, M.; Blayac, J. P.; Balmes, P. Cisplatin-induced Renal Toxicity and Toxicity-modulating Strategies: A Review. Cancer Chemother. Pharmacol. 1994, 35(1), 1–9. https://doi.org/10.1007/BF00686277
Mansouri-Torshizi, H.; Saeidifar, M.; Divsalar, A.; Saboury, A. A. Interaction Studies Between a 1,10-phenanthroline Adduct of Palladium(II) Dithiocarbamate Anti-tumor Complex and Calf Thymus DNA: Synthesis, Spectral, and In-vitro Study. Spectrochim. Acta, Part A 2010, 77(1), 312–318. https://doi.org/10.1016/j.saa.2010.05.029
Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-refractory Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 351(4), 337–345. https://doi.org/10.1056/NEJMoa033025
Mohelnikova-Duchonova, B.; Melichar, B.; Soucek, P. FOLFOX/FOLFIRI Pharmacogenetics: The Call for a Personalised Approach in Colorectal Cancer Therapy. World J. Gastroenterol. 2014, 20(30), 10316–10330. https://doi.org/10.3748/wjg.v20.i30.10316
Lim, R.; Sun, Y.; Im, S. A.; Liang, J. T.; Ahn, J. B.; Park, D. J.; Lee, M. A.; Sriuranpong, V.; Mulder, K.; Guo, Y.; Chen, Z.; Thongprasert, S.; Ba, Y.; Li, J.; Kim, T. W.; Yang, L.; Wang, X. W.; Kim, S. Y.; Han, S. W.; Roh, J. K.; Lou, M. A.; Kim, J. H.; Cheng, A. L. Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Patients: The ELSIE Study. World J. Gastroenterol. 2011, 17(14), 1879–1888. https://doi.org/10.3748/wjg.v17.i14.1879
Prewett, M. C.; Hooper, A. T.; Bassi, R.; Ellis, L. M.; Waksal, H. W.; Hicklin, D. J. Enhanced Anti-tumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) Against Human Colorectal Tumor Xenografts. Clin. Cancer Res. 2002, 8(3), 994–1003.
Qian, M.; Qian, D.; Jing, H.; Li, Y.; Ma, C.; Zhou, Y. Combined Cetuximab and Celecoxib Treatment Exhibits a Synergistic Anti-cancer Effect on Human Oral Squamous Cell Carcinoma In Vitro and In Vivo. Oncol. Rep. 2014, 32(4), 1681–1688. https://doi.org/10.3892/or.2014.3334
